1. Introduction {#sec1}
===============

The global incidence of coronary heart diseases (CHD) is still increasing, which underscores the need for novel and alternative approaches to prevent the initiation and progression of this disease already at an early stage. Since elevated serum low-density lipoprotein cholesterol (LDL-C) concentrations are causally related to CHD, most dietary life style interventions and pharmaceutical treatments to prevent CHD so far are focused on lowering serum LDL-C concentrations. Despite successful intervention possibilities, there is still a substantial residual cardiovascular risk. Therefore, a possibility of further lowering CHD risk is to target multiple metabolic pathways simultaneously \[[@B1], [@B2]\]. For example, statin treatment, to lower serum LDL-C concentrations, can be combined with other pharmaceutical agents, such as proprotein convertase subtilisin/kexin type 9 inhibitors, which substantially further lower serum LDL-C concentrations \[[@B3]\]. Also, the Niemann-Pick Like Intracellular Cholesterol Transporter 1 inhibitor ezetimibe can be used, which has been shown to further lower the number of myocardial infarctions with 13%, strokes with 14%, and ischemic strokes with 21% \[[@B4]\]. Besides combined interventions to further increase the LDL-C lowering potential, it can be considered to target at the same time other CHD risk parameters including serum high density lipoprotein (HDL) cholesterol (HDL-C), apolipoprotein A-I (apoA-I), triacylglycerol or lipoprotein(a) concentrations, and/or blood pressure \[[@B5]\]. These parameters may be interrelated. An inverse relationship exists, for example, between serum triacylglycerol and HDL-C concentrations. Thus, interventions that change triacylglycerol may therefore also affect HDL metabolism \[[@B6]\]. In this review we will however focus on possibilities to further reduce CHD risk via novel and alternative dietary and pharmacological interventions targeting apoA-I metabolism.

1.1. Increasing HDL Functionality by Increasing ApoA-I {#sec1.1}
------------------------------------------------------

So far, interventions specifically targeting to increase serum HDL-C concentrations did not report any protective cardiovascular effect, which has clearly negatively influenced the interest to develop novel interventions to elevate serum HDL-C. However, recent evidence suggests that the focus should be on optimizing HDL functionality instead of elevating circulating serum HDL-C concentrations \[[@B7]\]. By increasing their functionality, HDL particles are able to take up more cholesterol from peripheral tissues, that is, the so-called cholesterol efflux. In addition, a more functional HDL particle will be more antioxidative---in particular by inhibiting LDL oxidation---and more antithrombotic and will have a higher anti-inflammatory and antiapoptotic activity \[[@B8]\]. A wealth of evidence from epidemiological, in vitro, and in vivo studies suggests that higher apoA-I concentrations protect against CHD development \[[@B9]\]. By increasing apoA-I concentrations, the resulting newly produced small HDL particles (i.e., prebeta HDL) will be highly functional, thereby enhancing cholesterol efflux \[[@B8]\]. Indeed, it has been found that apoA-I concentration is the strongest predictor for cholesterol efflux capacity \[[@B10]\]. ApoA-I is the major protein of HDL particles \[[@B11]\] contributing to approximately 33% of the total HDL particle mass and up to 60% of the HDL protein mass \[[@B12]\]. The most likely mechanism explaining the beneficial effects of elevated serum apoA-I concentrations origins from the fact that apoA-I is the ligand for ATP-binding cassette transporter A1 (ABCA1), as such mediating cholesterol efflux from lipid-laden macrophages \[[@B8]\]. Based on this information, Smits et al. wrote a clear plead for strategies to increase serum apoA-I concentrations as the most promising target for enhancing HDL functionality, thereby decreasing cardiovascular disease (CVD) risk \[[@B13]\]. However, lowering CHD risk by increasing endogenous apoA-I production, by decreasing apoA-I degradation, or by providing exogenous apoA-I has for unknown reasons not yet been investigated into great detail. Therefore, the question remains whether specifically targeting apoA-I metabolism is a suitable target to reduce CHD risk.

In this review we will first briefly provide insight into the current knowledge of apoA-I synthesis, clearance, and degradation, followed by a detailed overview of dietary and novel experimental pharmaceutical developments targeting circulating apoA-I concentrations.

2. ApoA-I {#sec2}
=========

2.1. ApoA-I Synthesis {#sec2.1}
---------------------

ApoA-I mRNA is expressed in cells of the liver and small intestine \[[@B14]\], where it is translated into a pre-pro-apoA-I protein. The presegment needs cotranslational cleavage \[[@B15]\], which takes place during translocation of the protein into the endoplasmatic reticulum by a signal peptidase \[[@B16], [@B17]\]. This results in a stable intracellular, pro-apoA-I protein \[[@B15]\], which is secreted into blood and lymph. Directly after secretion of pro-apoA-I, the proprotein is cleaved of by Bone Morphogenetic Protein-1 (BMP-1) and Procollagen C-proteinase Enhancer-2 Protein (PCPE2) ([Figure 1](#fig1){ref-type="fig"}) \[[@B18], [@B19]\]. It is evident that the cleavage of the prosegment is essential for the secretion of newly formed intracellular apoA-I. Deletion of the coding sequence of the prosegment causes accumulation of apoA-I in the cell \[[@B20]\], decreases the efficiency of apoA-I mRNA expression \[[@B17]\], and impairs the secretion of apoA-I into blood and lymph \[[@B17], [@B20]\]. The cleavage of the proprotein occurs relatively rapid, while the residence time for pro-apoA-I in plasma is only 5.5 hours, in contrast to the residence time for mature apoA-I of 6.5 days \[[@B21]\]. About 4--8% of the circulating apoA-I pool is pro-apoA-I \[[@B15], [@B22], [@B23]\]. After cleavage of the prosegment, apoA-I accepts cholesterol and phospholipids from ABCA1 \[[@B24]\] to form a pre-*β* HDL particle ([Figure 1](#fig1){ref-type="fig"}). In other words, apoA-I is the starting point for the synthesis of a functional HDL particle and therefore essential for the formation and maturation of novel HDL particles \[[@B16]\]. In the circulation, lecithin-cholesterol acyltransferase esterifies the free cholesterol in these pre-*β* HDL particles, thereby forming HDL~3~ and finally HDL~2~ \[[@B25]\]. The ATP-binding cassette G1 transporter and scavenger receptor class B type 1 (SR-B1) contribute to the cholesterol efflux from peripheral tissues and macrophages to these mature HDL particles. After binding of HDL~2~ to SR-B1 on the liver, cholesterol esters are taken up and lipid-depleted apoA-I is returned to the circulation. These apoA-I-rich lipid-depleted HDL particles can again acquire cholesterol and phospholipids---forming an pre-*β* HDL particle---or can be cleared from the circulation \[[@B26]\].

2.2. ApoA-I Clearance {#sec2.2}
---------------------

Several organs are involved in apoA-I clearance and degradation \[[@B26]\]. Calculations in rabbits have indicated that renal apoA-I clearance accounts for approximately 68--70% of total apoA-I catabolism. Also in humans, the kidney is the major site for apoA-I clearance \[[@B26], [@B27]\]. In the kidneys, the uptake of HDL particles is limited, because the intact lipoprotein particles are too large to pass the glomerular filtration barrier. However, newly formed or recycled lipid free apoA-I can pass this barrier. In the proximal tubule of the glomerulus, apoA-I binds the receptors cubilin and megalin \[[@B28]\], which mediate endocytosis and delivery of the protein to the lysosomes \[[@B29], [@B30]\], resulting in complete degradation of the apoA-I protein. The amino acids can be reused for de novo protein synthesis \[[@B31]\]. While the kidney plays a major role in apoA-I degradation, the liver accounts for 26% of the apoA-I clearance, at least in rats. It is not known how the hepatocytes take up the apoA-I particles, but the apoA-I catabolic products are excreted from the liver via the bile into the gut. In the gut, they are further digested and absorbed or excreted from the body. Other tissues, besides kidney and liver, which are to a lesser extent involved in the degradation of apoA-I, are ovaries, adrenals, and spleen, which secrete apoA-I catabolic products into the urine ([Figure 1](#fig1){ref-type="fig"}) \[[@B26]\].

Increasing apoA-I concentrations via reducing apoA-I clearance is for unknown reasons not a subject of investigation. Consequently, it is also not known whether inhibiting apoA-I clearance affects HDL functionality. Therefore, decreasing apoA-I clearance is currently not a target for interventions, whereas elevating de novo apoA-I production certainly is \[[@B32]\].

3. Dietary Interventions Affecting ApoA-I Metabolism {#sec3}
====================================================

It has been clearly shown that dietary components can change serum apoA-I concentrations. We here provide an overview of randomized controlled dietary intervention studies that have examined the effects of whole foods and (non)nutrients on apoA-I concentrations or apoA-I metabolism. Only crossover and parallel studies were included. Potentially relevant studies published before January 2017 were identified by a systematic search of the database PubMed (<https://www.ncbi.nlm.nih.gov>). The following search terms were used to search in titles and abstracts: (((Clinical Trial\[Publication Type\]) OR randomized controlled trial\[Publication Type\])) AND apolipoprotein A^*∗*^\[MeSH Terms\]. The selection was performed in two steps. First, titles and abstracts were screened. Studies were selected if they met the following inclusion criteria: human intervention study with adults, dietary intervention study, and measurement of apoA-I concentrations. In the second step, full-texts of the selected articles were read to extract fasting or postprandial apoA-I values. Then, a search was performed to find meta-analysis of each food or (non)nutrient group. When a meta-analysis was found, it is included in this review together with the articles identified by us, which were not part of the meta-analysis. Changes in apoA-I concentrations were expressed as percentages, if possible. When percentages were not reported, they were calculated from the mean values as reported in the articles. Furthermore, the list of articles was screened for studies that investigated the effects on cholesterol efflux, apoA-I production rate (PR), or fractional catabolic rate (FCR).

3.1. Alcohol {#sec3.1}
------------

Based on a meta-analysis including 16 studies with in total 374 subjects, Brien et al. concluded that alcohol consumption (women: \>15 g alcohol/day; men: \>30 g alcohol/day) increased fasting plasma apoA-I concentrations with 10.1 mg/dL (95% CI 7.3--12.9 mg/dL) \[[@B33]\]. A later study, not included in this meta-analysis, also showed a higher fasting apoA-I concentration after alcohol consumption as compared with no alcohol consumption \[[@B34]\]. Moreover, postprandial apoA-I concentrations also increased after alcohol consumption \[[@B35]\]. These effects did not depend on the source (red wine, beer, and Dutch gin) of alcohol \[[@B36]\]. Lavy et al. however reported that red wine increased apoA-I as compared with white wine consumption \[[@B37]\]. Also, Gepner et al. observed that red wine increased apoA-I concentrations as compared with water consumption, but white wine did not significantly change apoA-I concentrations as compared with water or red wine \[[@B38]\]. Furthermore, alcohol consumption not only elevated circulating apoA-I concentrations but also improved HDL functionality as shown by an increased cholesterol efflux capacity \[[@B36], [@B39], [@B40]\]. In one study, the kinetics of apoA-I have been examined. It was reported that apoA-I PR increased and apoA-I FCR decreased after alcohol consumption ([Table 1](#tab1){ref-type="table"}) \[[@B41]\].

3.2. Boiled and Filtered Coffee, Caffeine, and Tea {#sec3.2}
--------------------------------------------------

In six studies, the effects of boiled or filtered coffee, caffeine, and tea on fasting apoA-I concentrations have been compared. In none of the studies, significant differences in apoA-I concentrations were observed ([Table 2](#tab2){ref-type="table"}) \[[@B42]--[@B47]\].

3.3. Fatty Acids {#sec3.3}
----------------

In a recent meta-analysis including 104 diets from forty-two well-controlled intervention studies the effects of the various fatty acids on fasting serum apoA-I concentrations were estimated. Effects of fish-fatty acids were not included in that meta-analysis and will be discussed in the next paragraph. A significant increase in serum apoA-I concentrations was found when 1 energy% of carbohydrates was replaced by saturated fatty acids (SFA; 8.4 mg/dL, 95% CI 6.4--10.5), cis-monounsaturated fatty acids (cis-MUFA; 5.5 mg/dL, 95% CI 3.7--7.3), and cis-polyunsaturated fatty acids (cis-PUFA; 2.3 mg/dL, 95% CI 0.1--4.6). cis-MUFA mainly referred to oleic acid and cis-PUFA to linoleic acid plus some *α*-linolenic acid. This meta-analysis further showed that fasting apoA-I concentrations were significantly increased by replacement of 1 energy% from carbohydrates with lauric acid (C12:0; 19.2 mg/dL, 95% CI 14.6--12.7), myristic acid (C14:0; 8.8 mg/dL, 95% CI 0.5--13.1), and palmitic acid (C16:0; 6.5 mg/dL, 95% CI 3.8--9.3), while replacement with stearic acid (C18:0) did not change apoA-I concentrations \[[@B48]\]. For these latter analyses, 88 diets from 34 studies were included. In another meta-analysis based on 17 diets from 10 studies, Brouwer (2016) described the effects of trans-fatty acids (TFA) on circulating fasting apoA-I concentrations. It was reported that replacement of 1 energy% of carbohydrates for total TFA increased apoA-I concentrations (3.3 mg/dL, 95% CI 4.7--1.9). When a difference was made between industrial and ruminant TFA, it was found that replacement with industrial TFA significantly increased fasting apoA-I concentrations (3.3 mg/dL, 95% CI 4.8--1.8), while ruminant TFA did not (4.6 mg/dL, 95% CI: −22.0--12.9). This may be due to a lack of power, since only two studies investigated ruminant TFA. Furthermore, this meta-analysis also showed that replacement of 1 energy% from TFA with SFA increased fasting apoA-I concentrations (2.6 mg/dL, 95% CI 1.4--3.9), while replacement with MUFA did not change apoA-I concentrations and replacement with cis-PUFA decreased fasting apoA-I concentrations (−1.7 mg/dL, 95% CI −2.8--−0.6) ([Table 3](#tab3){ref-type="table"}) \[[@B49]\].

Several studies have examined the effects of the various fatty acids on serum apoA-I metabolism. A TFA diet increased apoA-I FCR as compared with SFA, but the FCR after cis-PUFA consumption did not differ from the TFA or SFA diets. ApoA-I PR was not different between the various diets \[[@B50]\]. Moreover, a cis-PUFA diet did not affect apoA-I FCR \[[@B51]\] and both FCR and PR decreased after low fat consumption compared with high cis-MUFA consumption \[[@B52]\]. In contrast, Labonté et al. have reported that replacing 13 energy% of carbohydrates with cis-MUFA decreased apoA-I FCR with no change in apoA-I PR ([Table 3](#tab3){ref-type="table"}) \[[@B53]\]. The different results between these two studies \[[@B52], [@B53]\] may have been due to the significant weight loss in the study of Desroches et al., which may have confounded to some extent the effect of MUFA on apoA-I kinetics.

3.4. Fish and Fish-Fatty Acids {#sec3.4}
------------------------------

Most studies investigating the effects of omega-3 fatty acids from fatty fish, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), did not observe any differences in fasting and postprandial apoA-I concentrations \[[@B56], [@B57], [@B58]--[@B66], [@B67]--[@B72], [@B70]--[@B76]\]. However, in two studies, all in healthy men, fasting apoA-I concentrations decreased after fish oil supplementation. The first study showed lower apoA-I concentrations after pollock oil (rich in EPA) and salmon oil (rich in DHA), but not after tuna oil (rich in DHA) consumption as compared with butter \[[@B77]\]. The second study found lower apoA-I concentrations after EPA oil supplementation compared with DHA oil supplementation \[[@B78]\]. On the other hand, one study found an increase in fasting apoA-I concentrations after a diet high in fish-fatty acids compared with a diet low in fish-fatty acids. In this study, the diets were matched for total fat ([Table 4](#tab4){ref-type="table"}) \[[@B79]\].

Five studies have investigated the effects of fish on fasting apoA-I concentrations. In one study, fatty fish (salmon, rainbow trout, Baltic herring, whitefish, vendace, and tuna) consumption increased apoA-I concentrations compared with lean fish (pike, pike-perch, perch, saithe, and cod) consumption. However, it did not change apoA-I concentrations as compared with lean meat (beef and pork) consumption \[[@B80]\]. The other three studies did not find differences in apoA-I concentrations after fish consumption, of which two compared fatty fish with lean meat \[[@B81], [@B82]\] and one compared prawns with crab \[[@B83]\]. A limitation of the study of Lindqvist et al. is that participants consumed in total 35 energy% of fat in the herring period and only 10 energy% of fat in the meat period \[[@B81]\], which may have affected apoA-I concentrations. Comparisons between fish and meat consumption are probably not confounded by differences in the intake of the source of protein, as suggested by Gascon et al. In that study, the effects of proteins in lean fish (cod, sole, pollack, and haddock) were compared with those of animal protein (lean beef, pork, veal, eggs, skimmed milk, and milk products). No differences on fasting apoA-I concentrations were found ([Table 4](#tab4){ref-type="table"}) \[[@B84]\].

3.5. Fibers {#sec3.5}
-----------

Studies comparing the effects of oat germ, low in fiber, with those of wheat germ, high in fiber, consumption did not find any differences in fasting apoA-I concentrations \[[@B88], [@B85]--[@B90]\]. In four of these studies, it was explicitly reported that the macronutrient composition of the experimental diets was comparable \[[@B88], [@B85], [@B86], [@B89]\]. Mekki et al. observed that a high-fiber diet did not change fasting apoA-I concentrations as compared with a low fiber diet \[[@B91]\]. On the other hand, decreased fasting apoA-I concentrations were found after a high *β*-glucan and psyllium diet as compared with a low fat, low-cholesterol control diet \[[@B92]\]. The water-soluble fiber arabinoxylan also decreased fasting apoA-I concentrations as compared with the control diet, which had a similar macronutrient composition \[[@B93]\]. Furthermore, no differences in fasting apoA-I concentrations were observed between the soluble and insoluble forms of*P*.*ovate* \[[@B94]\]. The water-soluble fiber *β*-glucan did not affect fasting apoA-I concentrations \[[@B95]\]. Furthermore, wheat germ consumption increased fasting apoA-I concentrations compared with flaxseed consumption ([Table 5](#tab5){ref-type="table"}) \[[@B96]\].

3.6. Nuts {#sec3.6}
---------

In one short-term study, walnut consumption significantly increased fasting serum apoA-I concentrations \[[@B97]\], but these effects were not found in two longer-term studies \[[@B98], [@B99]\]. Almond consumption did also not affect fasting apoA-I concentrations \[[@B100], [@B101]\]. Likewise, hazelnuts \[[@B102], [@B103]\] and pistachio nuts did not change fasting apoA-I concentrations \[[@B104]\]. A limitation of some of the studies is that not all experimental diets were matched for differences in fat and fatty acid composition. In some of these studies, the diets containing nuts provided more energy from fat than the control diets \[[@B99]--[@B102]\]. Furthermore, the nut diets were sometimes also lower in SFA and higher in PUFA than the control diets \[[@B99], [@B101]\]. Although these differences in nutrient intakes are inherent to consuming more nuts, it is not likely that the effects observed are due to minor component in nuts, since fatty acids increase apoA-I concentrations as compared with carbohydrates \[[@B48]\]. However, most other studies that used a control diet with similar fat and fatty acid composition did also not find any effects of the consumption of nuts on apoA-I concentrations ([Table 6](#tab6){ref-type="table"}) \[[@B98], [@B103], [@B104]\].

3.7. Plant Sterols and Stanols {#sec3.7}
------------------------------

Most studies examining the effects of plant sterols on serum lipids did not demonstrate an effect of plant sterols on fasting apoA-I concentrations \[[@B111], [@B105], [@B107]--[@B109]\]. In one study, comparing olive oil and olive oil with plant sterol esters and sunflower oil with plant sterol esters, fasting apoA-I concentrations increased when plant sterol esters were consumed together with olive oil, but apoA-I concentrations were comparable during the other two interventions \[[@B113]\]. Furthermore, one study showed an increase in fasting apoA-I concentrations comparing 3 months of prudent diet consumption (National Cholesterol Education Program) with added plant sterols, with prudent diet consumption alone \[[@B106]\]. One study examined the effects of plant stanols on fasting apoA-I concentrations and found increased apoA-I concentrations comparing 6 weeks of sitostanol consumption with no sitostanol consumption \[[@B114]\]. Finally, no changes in apoA-I PR and FCR were found after plant sterol or stanol consumption ([Table 7](#tab7){ref-type="table"}) \[[@B114], [@B108]\].

3.8. Soy Proteins or Isoflavones Isolated from Soy {#sec3.8}
--------------------------------------------------

Studies investigating the effects of soy protein on fasting apoA-I concentrations showed inconsistent outcomes. Eight studies using different amounts of soy protein for 3 weeks till 3 months did not find changes in fasting apoA-I concentrations \[[@B115], [@B120], [@B119]--[@B122], [@B123]--[@B117]\]. On the other hand, in one study products containing soy protein increased fasting apoA-I concentrations as compared with products containing casein \[[@B124]\], while in another study products with soy protein decreased fasting apoA-I as compared with products containing casein \[[@B125]\]. Furthermore, two studies found different effects of various soy products on fasting apoA-I concentrations \[[@B127], [@B126]\]. Soy-milk increased apoA-I concentrations as compared with soy nuts and soy flour, but no differences were found as compared with animal protein \[[@B127]\]. Soy nut and soy protein consumption increased apoA-I concentrations as compared with the control group without soy \[[@B126]\]. Two studies have investigated the effects of isoflavones isolated from soy on apoA-I concentrations and showed no effect on fasting \[[@B129], [@B128]\] and postprandial apoA-I concentrations ([Table 8](#tab8){ref-type="table"}) \[[@B128]\].

3.9. Others {#sec3.9}
-----------

Many other products and food components have been studied for their effects on apoA-I concentrations. In most of these studies, which included eggs \[[@B130]\], dried garlic \[[@B131], [@B132]\], beta-carotene \[[@B133]\], phytochemicals with cytochrome P-450-inducing activity \[[@B134]\], magnesium \[[@B135]\], eggplant \[[@B136]\], dry beans \[[@B137]\], kiwifruits \[[@B138]\], and polyphenols \[[@B139]\], no effects on fasting apoA-I concentrations were observed. In addition, sphingolipids did not change postprandial apoA-I concentrations \[[@B140]\]. On the other hand, red grape juice \[[@B141]\], a mixture of citrus flavonoids and tocotrienols \[[@B142]\], vitamin D supplementation \[[@B143], [@B144]\], vitamin D plus calcium supplementation \[[@B144]\], theobromine \[[@B145]\], orange juice \[[@B146]\], and a high dose of grape pomace and omija fruit \[[@B147]\] all increased fasting apoA-I concentrations ([Table 9](#tab9){ref-type="table"}).

4. Pharmacological Approaches Targeting ApoA-I Metabolism {#sec4}
=========================================================

Although not always specifically developed for this purpose, several well-known drugs like statins \[[@B7], [@B148]\] and CETP inhibitors \[[@B149]--[@B152]\] affect serum apoA-I concentrations. However, since this review focuses on novel strategies to increase serum apoA-I concentrations, we here describe only approaches that are currently in development and are specifically designed to target a change in apoA-I metabolism. Potentially relevant studies published before January 2017 were identified by a systematic search of the database PubMed (<https://www.ncbi.nlm.nih.gov>). The following search terms were used to search in titles and abstracts: (Pharmacological AND approaches AND apoA-I). First, all abstracts were screened and the pharmacological approaches were divided into three categories: apoA-I mimetics, apoA-I infusions, and others. Second, a new search was performed with the search terms: (apoA-I mimetics AND apoA-I infusions AND RVX-208 AND LCAT infusion AND clinical trial) to select all studies published before January 2017 that investigate apoA-I mimetics, apoA-I infusions, and RVX-208 in humans.

4.1. ApoA-I Mimetics {#sec4.1}
--------------------

ApoA-I mimetics are small amphipathic peptides that resemble apoA-I in biological function and structure \[[@B153]\]. These mimetics are not the intact apoA-I protein, but small fragments of the protein with certain biological functions. These small peptides can be given orally or can be infused \[[@B15], [@B154]\]. To prevent digestion in the gastrointestinal tract, mimetics are made from D-amino acids, which are resistant to human gastrointestinal proteolytic enzymes \[[@B14]\]. Over the years, several mimetics have been produced, but none of them has all the antiatherogenic functions of apoA-I. However, combining several mimetics can be a theoretical approach to mimic all antiatherosclerotic properties of apoA-I \[[@B155]\]. The only mimetic that has been tested in humans is D-4F. When 50 patients with coronary artery disease received a single oral dose (30, 100, 300, and 500 mg) of this mimetic, the two highest doses increased the anti-inflammatory activity of the HDL fraction. However, no changes in lipids or lipoprotein concentrations were seen. D-4F was shown to be safe and well tolerated ([Table 10](#tab10){ref-type="table"}) \[[@B156]\]. Unfortunately, the effects of D-4F on cholesterol efflux in humans have not yet been investigated.

4.2. ApoA-I Infusions {#sec4.2}
---------------------

Besides apoA-I mimetics, apoA-I itself, either by using delipidated HDL or by using delipidated HDL combined with phospholipids, can be infused directly into the circulation. The theoretical advantage of using apoA-I or apoA-I-phospholipid complexes instead of using apoA-I mimetics is that the apoA-I protein is completely intact and still possesses all its biological functions and might therefore have a larger atheroprotective effect. So far, three different forms of apoA-I have been tested, that is, apoA-I Milano (MDCO-216), CSL-111/CSL112, and CER-001.

### 4.2.1. ApoA-I Milano {#sec4.2.1}

In a randomized human controlled trial, 47 patients with acute coronary syndromes received for 5 weeks one infusion of placebo or recombinant apoA-I Milano/phospholipid complex (ETC-216) at 15 or 45 mg/kg per week. At the end of the study a significant reduction in atheroma volume was found in the high dose group \[[@B157]\]. This reduction in atheroma volume was accompanied by a reduction in external elastic membrane volume of the artery, but not with a change in lumen volume \[[@B158]\]. Recently, in a randomized controlled study, patients with stable coronary artery disease received 5 doses of 10, 20, 30, and 40 mg/kg MDCO-216 infusion. This resulted in a dose-dependent increase in apoA-I concentrations and a dose-dependent shift from small- to large-sized HDL particles \[[@B159]\]. Moreover, a profound increase in ABCA1-mediated cholesterol efflux was observed \[[@B160]\]. However, very recently the MILANO-PILOT study failed to slow down the regression of coronary atherosclerosis with 5 weekly infusions of 20 mg/kg MDCO-216 in 120 patients with acute coronary syndromes. In fact, significant reductions in HDL-C and apoA-I concentrations were observed, while there were no effects found on percent atheroma volume and total atheroma volume ([Table 10](#tab10){ref-type="table"}) \[[@B161]\].

### 4.2.2. CSL-111/CSL112 {#sec4.2.2}

In one clinical study, 40 and 80 mg/kg CSL-111 were infused once a week for one month in 183 patients elected for coronary angiography. Treatment of the high dose group (80 mg/kg) was discontinued early, because some of the patients exceeded the upper level of alanine aminotransferase by 100-fold. The low dose group (40 mg/kg) showed a significant reduction in atheroma volume. However, this reduction was not significantly different from the decrease in the placebo group \[[@B162]\]. After this, the further development program of CSL-111 was discontinued because of the unfavorable hepatic abnormalities. As a follow-up, one phase I study has been performed using CSL112, which is a similar compound, but postulated without effects on liver function. In this study, a single dose (5, 15, 40, 70, 105, or 135 mg/kg) or multiple doses for 4 weeks (3.4 or 6.7 g once a week or 3.4 g twice a week) of CSL112 was administrated intravenously to healthy volunteers. Both the single and multiple doses of CSL112 dose dependently increased serum apoA-I and serum HDL-C concentrations. Moreover, also pre-*β* HDL particle concentrations and cholesterol efflux capacity were increased. In the single dose study, dose-dependent effects were found on HDL-C \[[@B163], [@B164]\]. Recently, two studies showed that CSL112 was indeed safe for human consumption, with no effects on liver function parameters \[[@B166], [@B165]\]. In the first study, patients with atherosclerosis were given infusions of 1.7, 3.4, and 6.8 g CSL112 or placebo. The CSL112 infusions resulted in a dose-dependent increase in apoA-I and total cholesterol efflux \[[@B166]\]. In the second study patients with myocardial infarction received infusions of 2 or 6 g CSL112 or placebo for 4 weeks. Here also a dose-dependent increased in HDL-C, apoA-I, and cholesterol efflux was shown ([Table 10](#tab10){ref-type="table"}) \[[@B165]\].

### 4.2.3. CER-001 {#sec4.2.3}

In one clinical study, 417 patients with acute coronary syndromes were randomized for 6 weekly infusions of 3, 6, and 12 mg/kg CER-001 or placebo. No changes in atheroma volumes were found. It was speculated that a higher dose or a different patient group would have shown more positive results \[[@B167]\]. In a recent human study, 9 infusions of 8 mg/kg CER-001 were given twice weekly for 28 days to 7 patients with familial hypoalphalipoproteinemia, who were severely deficient in HDL. In this patient group, CER-001 significantly increased serum apoA-I and HDL-C concentrations and reduced atherosclerotic lesion size, measured using Magnetic Resonance Imaging. Moreover, an increase in cholesterol efflux from macrophages and a higher fecal neutral sterol excretion was seen, which may indicate improved RCT \[[@B168]\]. Additionally, 12 biweekly infusions with 8 mg/kg CER-001 showed increased apoA-I concentrations, a decrease in vessel wall area, and a trend toward a reduction in vessel wall thickness \[[@B169]\]. Recently, a study evaluated the effects of 3 mg/kg CER-001, in patients with atherosclerotic carotid artery disease, and showed increased apoA-I concentrations, with a simultaneously increased cholesterol efflux capacity \[[@B170]\]. Unfortunately, preliminary data of a recent clinical trial in patients with coronary atherosclerosis did not show beneficial effects of CER-001 on atheroma volume and LDL-C \[[@B171]\] ([Table 10](#tab10){ref-type="table"}).

4.3. Others {#sec4.3}
-----------

### 4.3.1. RVX-208 {#sec4.3.1}

The first class of compounds affecting apoA-I metabolism refers to the apoA-I transcriptional upregulator RVX-208. RVX-208 is an oral, small synthetic quinazoline molecule, which binds bromo- and extra terminal (BET) proteins and upregulates apoA-I gene transcription via an epigenetic mechanism.

In the first human clinical trial, 18 healthy subjects received varying and multiple doses (1 to 20 mg/kg per day) of RVX-208 or placebo for 7 days. Plasma apoA-I concentrations were increased, and more importantly, an increase in pre-*β*1-HDL concentrations and a higher ABCA1-mediated cholesterol efflux was demonstrated \[[@B172]\]. The outcome of the recent phase 2 randomized placebo-controlled clinical ASSERT trial, evaluating the effect of RVX-208 on serum apoA-I concentrations and CHD risk in human, was less positive. In that study, 299 patients with stable coronary artery disease received placebo or RVX-208 at three different dosages (50, 100, and 150 mg) twice daily for 12 weeks. Only a nonsignificant increase in serum apoA-I concentrations was found. Unfortunately, HDL functionality and cholesterol efflux capacity were not studied \[[@B173]\]. A second study using RVX-208 is the phase 2b clinical trial SUSTAIN. In this trial, 172 statin-treated patients (Rosuvastatin or Atorvastatin) with low serum HDL-C concentrations were treated with 200 mg/day RVX-208 for 24 weeks. Both serum apoA-I concentrations and HDL particle numbers increased significantly. Furthermore, RVX-208 was found to be safe for oral use \[[@B174]\]. In another phase 2 clinical trial, the ASSURE study, 323 statin (Rosuvastatin or Atorvastatin) treated patients with coronary artery disease and low serum HDL-C concentrations received 100 mg RVX-208 twice daily for 26 weeks. However, no significant reductions in atheroma volume or increases in HDL-C and apoA-I concentrations were seen \[[@B32]\]. Finally, a recent study in subjects with prediabetes showed that 100 mg RVX-208 for 29--33 days did not increase HDL-C and apoA-I concentrations, while it increased the concentration of medium-sized HDL and decreased the concentration of small-sized HDL particles. Furthermore, RVX-208 delayed and reduced oral glucose absorption and endogenous glucose production ([Table 10](#tab10){ref-type="table"}) \[[@B175]\].

### 4.3.2. LCAT Infusion {#sec4.3.2}

The first human study investigating the effects of lecithin-cholesterol acyltransferase (LCAT) infusion investigated only one patient with familial LCAT deficiency. Recombinant human LCAT was infused 3 times for 1 hour in a dose optimization phase (0.3, 3.0, and 9.0 mg/kg) and after this 1 to 2 weekly infusions were given of 3.0 or 9.0 mg/kg for 7 months. LCAT infusion improved renal function, increased apoA-I, HDL-C, and to a lesser extent LDL-C. Furthermore, after infusion, postprandial triacylglycerol concentrations decreased \[[@B176]\]. These results are promising; however, before drawing conclusions about LCAT infusion clinical trials including more patients should be done.

5. Conclusion {#sec5}
=============

Alcohol consumption increases fasting apoA-I concentrations and may improve cholesterol efflux, possibly via increasing apoA-I PR and decreasing FCR. Further, replacement of carbohydrates for SFA, cis-MUFA, cis-PUFA, and TFA increases fasting apoA-I concentrations. The effects of the various SFA are different, since lauric, palmitic, and myristic acids increase apoA-I concentrations, while stearic acid does not. The different fatty acids affect apoA-I metabolism differently, but results are conflicting. Therefore more studies are needed to better understand the effects of the various macronutrients on apoA-I kinetics.

Coffee, caffeine, tea, omega 3 fatty acid, fish, nuts, plant sterol and stanol, different soy proteins, and isoflavones isolated from soy do not change fasting apoA-I concentrations. Moreover, the effects of the various types of fibers may be different; the consumption of diets rich in wheat germ did not modify apoA-I concentrations, while the consumption of diets rich in psyllium, arabinoxylan, and flaxseed may decrease fasting apoA-I concentrations. However, these types of fibers have only been examined in a limited number of studies. Therefore, we conclude that fiber consumption does not have a profound impact on fasting apoA-I concentrations.

Finally, five other food components showed a promising increase in fasting apoA-I concentrations: citrus, vitamin D, theobromine, orange juice, and a high dose of grape pomace and omija fruit. However, these findings need to be confirmed in future studies. Additional research is also needed to examine the effects of these products or food components not only on apoA-I kinetics, but also on HDL functionality.

Overall, all three categories of pharmacological approaches showed that targeting apoA-I concentrations and/or HDL functionality by a pharmacologic approach can increase apoA-I functionality and might improve CHD risk markers, including vessel wall characteristics and inflammation. The mimetic D-4F is promising, but clinical studies are required to investigate the effects on HDL functionality. The CSL112 and LCAT infusions are the most promising of the infusion therapies, but studies are needed to investigate the effects of CSL112 on CHD risk markers, including vessel wall characteristics and inflammation, and LCAT infusions need to be investigated in clinical trials with more patients. Unfortunately, recent clinical studies showed no improvement in CHD risk markers after apoA-I Milano, RVX-208, or CER-001 therapy.

Although we cannot exclude that we have missed studies during the systematic searches and studies with positive results are overrepresented, we conclude that both dietary components and pharmacological approaches can be used to increase apoA-I concentrations. For the dietary components in particular, more knowledge about underlying mechanisms is necessary, as increasing apoA-I per se does not necessarily translate into a reduced CHD risk.
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![Simplified scheme of the synthesis, metabolism, and clearance of apoA-I. ApoA-I is synthesized in cells of the liver and intestine as pre-pro-apoA-I. After translocation to the endoplasmic reticulum, the preprotein is cleaved of and pro-apoA-I is secreted into blood and lymph. In the circulation, the prosegment is directly cleaved of by Bone Morphogenetic Protein-1 (BMP-1) and Procollagen C-proteinase Enhancer-2 Protein (PCPE2). After this, apoA-I accepts cholesterol and phospholipids from ABCA1, forming a pre-*β* HDL particle. In the circulation, lecithin-cholesterol acyltransferase esterifies (LCAT) the free cholesterol in these pre-*β* HDL particles, forming HDL~3~ and finally HDL~2~, as indicated by the black arrows. After binding of HDL~2~ to SR-B1 on the liver, the cholesterol esters are taken up and lipid-depleted apoA-I is returned to the circulation. These apoA-I-rich particles can again acquire cholesterol and phospholipids or can be cleared from the circulation. Clearance will take place for 70% by the kidney, where apoA-I is broken down into amino acids and ultimately excreted in the urine. 26% of the free apoA-I will be cleared by the liver, and apoA-I catabolic products will then be excreted via biliary secretion into the gut and further digested and absorbed or excreted from the body through the feces. 4% of the free apoA-I will go to other tissues and finally will end up in the urine, as indicated by the blue arrows.](JNME2017-5415921.001){#fig1}

###### 

Effect of alcohol consumption on apoA-I concentrations, HDL functionality, and apoA-I kinetics.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                       Food component/product                               Study design and duration   Participants                                 Intake                                               Effects
  ---------------------------------------- ---------------------------------------------------- --------------------------- -------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Brien et al. (2011) \[[@B33]\]           Alcohol                                              Meta-analysis of\           374 subjects                                 Women \> 15 g/day\                                   \(i\) 10.1 mg/dL (95% CI 7.3--12.9) ↑ in fasting plasma apoA-I concentrations
                                                                                                16 studies till 2009\                                                    Men \> 30 g/day                                      
                                                                                                (i) RCT with 2 arms\                                                                                                          
                                                                                                (ii) before versus after\                                                                                                     
                                                                                                \>1 week                                                                                                                      

                                                                                                                                                                                                                              

  Lavy et al. (1994) \[[@B37]\]            Red versus white wine                                RCT parallel\               20 healthy men                               44 g alcohol/day                                     \(i\) 12.0% ↑ in fasting plasma apoA-I concentrations comparing red wine with white wine
                                                                                                2 weeks                                                                                                                       

                                                                                                                                                                                                                              

  van der Gaag et al. (1999) \[[@B35]\]    Red wine versus beer versus Dutch gin versus water   RCT crossover\              11 healthy men                               40 g alcohol/day from red wine, beer, or Dutch gin   \(i\) 8.2% ↑ in fasting serum apoA-I concentrations comparing alcohol with water^*∗*^ \
                                                                                                3 weeks                                                                                                                       (ii) 9.2% ↑ in postprandial serum apoA-I concentrations comparing alcohol with water^*∗*^ \
                                                                                                                                                                                                                              (iii) No differences between the different beverages

                                                                                                                                                                                                                              

  van der Gaag et al. (2001) \[[@B36]\]    Red wine versus beer versus Dutch gin versus water   RCT crossover\              11 healthy men                               40 g alcohol/day from red wine, beer, or Dutch gin   \(i\) 10% ↑ in fasting plasma apoA-I concentrations comparing alcohol with water^*∗*^ \
                                                                                                3 weeks                                                                                                                       (ii) 6.2% ↑ in cholesterol efflux comparing alcohol with water^*∗*^ \
                                                                                                                                                                                                                              (iii) No differences between the different beverages

                                                                                                                                                                                                                              

  Beulens et al. (2004) \[[@B39]\]         Whisky versus water                                  RCT crossover\              23 healthy men                               40 g alcohol/day                                     \(i\) 6.2% ↑ in fasting plasma apoA-I concentrations\
                                                                                                17 days                                                                                                                       (ii) 17.5% ↑ in cholesterol efflux

                                                                                                                                                                                                                              

  Kralova Lesna et al. (2009) \[[@B40]\]   Beer versus nonalcoholic beverage                    RCT crossover\              13 healthy men                               36 g alcohol/day                                     \(i\) 7.5% ↑ in fasting plasma apoA-I concentrations^*∗*^ \
                                                                                                4 weeks                                                                                                                       (ii) 8.0% ↑ in fasting cholesterol efflux^*∗*^

                                                                                                                                                                                                                              

  Gepner et al. (2015) \[[@B38]\]          Red versus white wine versus water                   RCT parallel\               195 patients with diabetes mellitus type 2   17 g alcohol/day                                     \(i\) 2.3% ↑ in fasting plasma apoA-I concentrations comparing red wine with water^*∗*^ \
                                                                                                2 years                                                                                                                       (ii) No difference between white wine and water or red wine

                                                                                                                                                                                                                              

  Chiva-Blanch et al. (2013) \[[@B34]\]    Red wine versus dealcoholized red wine versus gin    RCT crossover\              67 men at high CVD risk                      30 g alcohol/day                                     \(i\) 12.5% and 12.6% ↑ in fasting plasma apoA-I concentrations comparing dealcoholized red wine with red wine and gin, respectively^*∗*^
                                                                                                4 weeks                                                                                                                       

                                                                                                                                                                                                                              

  Gottrand et al. (1999) \[[@B41]\]        Red wine versus nonalcoholic beverage                RCT\                        5 healthy men                                50 g alcohol/day                                     \(i\) 20% ↑ in plasma apoA-I pool\
                                                                                                4 weeks                                                                                                                       (ii) 10% ↑ in PR\
                                                                                                                                                                                                                              (iii) 6% ↓ in FCR
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Percentages calculated from the mean values; PR: production rate; FCR: fractional catabolic rate.

###### 

Effect of boiled and filtered coffee, caffeine, and tea on fasting apoA-I concentrations.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                            Food component/product                                   Study design and duration   Participants                                Intake           Effects
  --------------------------------------------- -------------------------------------------------------- --------------------------- ------------------------------------------- ---------------- ------------------------------------------------------
  Aro et al. (1987) \[[@B43]\]                  Boiled versus filtered coffee versus tea                 RCT crossover\              42 hypercholesterolemic subjects            8 cups/day       \(i\) No differences in serum apoA-I concentrations
                                                                                                         4 weeks                                                                                  

                                                                                                                                                                                                  

  Aro et al. (1990) \[[@B42]\]                  Boiled versus filtered coffee                            RCT crossover\              41 healthy subjects                         2--14 cups/day   \(i\) No differences in serum apoA-I concentrations
                                                                                                         4 weeks                                                                                  

                                                                                                                                                                                                  

  van Dusseldorp et al. (1991) \[[@B47]\]       Filtered versus unfiltered coffee versus no coffee       RCT parallel\               64 healthy subjects                         6 cups/day       \(i\) No differences in serum apoA-I concentrations
                                                                                                         79 days                                                                                  

                                                                                                                                                                                                  

  Burr et al. (1989) \[[@B44]\]                 Decaffeinated versus no coffee                           RCT crossover\              54 healthy subjects                         \>5 cups/day     \(i\) No differences in plasma apoA-I concentrations
                                                                                                         4 weeks                                                                                  

                                                                                                                                                                                                  

  Davies et al. (2003) \[[@B45]\]               Black tea versus caffeine versus caffeine free placebo   RCT crossover\              15 mildly hypercholesterolemic subjects     5 cups/day       \(i\) No differences in plasma apoA-I concentrations
                                                                                                         3 weeks                                                                                  

                                                                                                                                                                                                  

  Mozaffari-Khosravi et al. (2009) \[[@B46]\]   Sour tea versus black tea                                RCT parallel\               53 patients with diabetes mellitus type 2   2 cups/day       \(i\) No differences in serum apoA-I concentrations
                                                                                                         1 month                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Meta-analysis showing the effects of fatty acids on fasting apoA-I concentrations and studies showing effects of fatty acids on apoA-I kinetics.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                   Food component/product                                                                                                Study design and duration                      Participants                   Intake                           Effect
  ------------------------------------ --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------ -------------------------------- -----------------------------------------------------------------------------------------------------------
  Mensink (2016) \[[@B48]\]            Replacement of carbohydrates (carbs) for SFA, MUFA, or PUFA                                                           Meta-analysis of\                              Healthy subjects               1% of dietary energy             \(i\) 8.4 mg/dL (95% CI 6.4--10.5) ↑ in fasting apoA-I concentrations replacing carbs with SFA\
                                                                                                                                                             42 studies till Dec 2013\                                                                                      (ii) 5.5 mg/dL (95% CI 3.7--7.3) ↑ in fasting apoA-I concentrations replacing carbs with MUFA\
                                                                                                                                                             Daily controlled RCT parallel and crossover\                                                                   (iii) 2.3 mg/dL (95% CI 0.1--4.6) ↑ in fasting apoA-I concentrations replacing carbs with PUFA
                                                                                                                                                             \>13 days                                                                                                      

                                                                                                                                                                                                                                                                            

  Mensink (2016) \[[@B48]\]            Replacement of carbs for lauric acid (C12:0), myristic acid (C14:0), palmitic acid (C16:0), or stearic acid (C18:0)   Meta-analysis of\                              Healthy subjects               1% of dietary energy             \(i\) 19.2 mg/dL (95% CI 14.6--12.7) ↑ in fasting apoA-I concentrations replacing carbs with lauric acid\
                                                                                                                                                             34 studies till Dec 2013\                                                                                      (ii) 8.8 mg/dL (95% CI 0.5--13.1) ↑ in fasting apoA-I concentrations replacing carbs with myristic acid\
                                                                                                                                                             Daily controlled RCT parallel and crossover\                                                                   (iii) 6.5 mg/dL (95% CI 3.8--9.3) ↑ in fasting apoA-I concentrations replacing carbs with palmitic acid\
                                                                                                                                                             \>13 days                                                                                                      (iv) No difference in apoA-I concentrations replacing carbs with stearic acid

                                                                                                                                                                                                                                                                            

  Brouwer (2016) \[[@B49]\]            Replacement of trans-fatty acids (TFA) for carbs                                                                      Meta-analysis of\                              Healthy subjects               1% of dietary energy             \(i\) 3.3 mg/dL (95% CI 4.7--1.9) ↑ in fasting apoA-I concentrations replacing carbs with TFA\
                                                                                                                                                             10 studies till Sep 2014\                                                                                      (ii) 2.6 mg/dL (95% CI 1.4--3.9) ↑ in fasting apoA-I concentrations replacing TFA with SFA\
                                                                                                                                                             Daily controlled RCT parallel and crossover\                                                                   (iii) No difference in apoA-I concentrations replacing TFA with MUFA\
                                                                                                                                                             \>13 days                                                                                                      (iv) 1.7 mg/dL (95% CI −2.8--−0.6) ↓ in fasting apoA-I concentrations replacing TFA with PUFA

                                                                                                                                                                                                                                                                            

  Ginsberg et al. (1994) \[[@B51]\]    Average American diet versus PUFA enriched diet                                                                       RCT parallel\                                  21 healthy men                 MUFA: 14 versus 8 energy%\       \(i\) No difference in apoA-I FCR
                                                                                                                                                             6 weeks                                                                       PUFA: 7 versus 13 energy%        

                                                                                                                                                                                                                                                                            

  Desroches et al. (2004) \[[@B52]\]   Low fat diet versus high MUFA diet                                                                                    RCT parallel\                                  18 healthy men                 Fat: 25.8 versus 40.1 energy%\   \(i\) 31% ↓ PR after low fat compared with high MUFA diet\
                                                                                                                                                             6-7 weeks                                                                     MUFA: 13.3 versus 22.5 energy%   (ii) 22% ↓ FCR after low fat compared with high MUFA diet

                                                                                                                                                                                                                                                                            

  Matthan et al. (2004) \[[@B50]\]     Soybean oil (PUFA) versus margarine (TSA) versus butter (SFA)                                                         RCT crossover\                                 8 hypercholesterolemic women   2/3 of the total fat intake      \(i\) 11% ↑ FCR after margarine compared with butter\
                                                                                                                                                             5 weeks                                                                                                        (ii) No difference in PR between the diets

                                                                                                                                                                                                                                                                            

  Labonté et al. (2013) \[[@B53]\]     Carbohydrates versus MUFA                                                                                             RCT parallel\                                  16 dyslipidemic subjects       13 energy%                       \(i\) 5.6% ↑ in FCR after carbohydrate compared with MUFA consumption\
                                                                                                                                                             4 weeks                                                                                                        (ii) No difference in PR between the diets
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, TFA: trans-fatty acids, PR: production rate, and FCR: fractional catabolic rate.

###### 

Effect of fish oil or fish on apoA-I concentrations.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                     Food component/product                                                                                                                                                     Study design and duration   Participants                                                     Intake                                                       Effect
  -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ---------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------
  Schectman et al. (1988) \[[@B56]\]     Low versus high fish oil versus safflower oil capsules                                                                                                                     RCT crossover\              13 patients with noninsulin-dependent diabetes mellitus type 2   4.0 versus 7.5 g omega-3/day\                                \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    1 month                                                                                      12 g safflower oil/day                                       

                                                                                                                                                                                                                                                                                                                                                                              

  Wilt et al. (1989) \[[@B57]\]          Fish oil versus safflower oil capsule                                                                                                                                      RCT parallel\               38 healthy men                                                   20 g/day                                                     \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    12 weeks                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Childs et al. (1990) \[[@B77]\]        Pollock oil (EPA) versus tuna (DHA) versus salmon (DHA) versus butter capsule                                                                                              RCT crossover\              8 healthy men                                                    EPA: 11.7, 5.4, and 6.1 g/day\                               \(i\) 22.0% ↓ in fasting plasma apoA-I concentrations comparing pollock oil with control\
                                                                                                                                                                                                                    3 weeks                                                                                      DHA: 3.1, 15.5, and 7.7 g/day                                (ii) 14.0% ↓ in fasting plasma apoA-I concentrations comparing salmon oil with control\
                                                                                                                                                                                                                                                                                                                                                                              (iii) No differences in fasting plasma apoA-I concentrations comparing tuna oil with control

                                                                                                                                                                                                                                                                                                                                                                              

  DeLany et al. (1990) \[[@B58]\]        Low versus high fish oil versus margarine (similar macronutrient composition)                                                                                              RCT parallel\               15 healthy men                                                   0, 5, and 20 g fish oil/day with 0, 2, and 8 g omega-3/day   \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    5 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Levinson et al. (1990) \[[@B59]\]      Fish oil versus vegetable oil capsule                                                                                                                                      RCT parallel\               16 mild hypertensive patients                                    50 g oil/day, 9 g EPA, and 6 g DHA                           \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    6 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Mori et al. (1990) \[[@B60]\]          Fish oil versus no fish oil                                                                                                                                                RCT parallel\               22 insulin-dependent diabetic men                                2.7 g EPA and 1.7 g DHA/day                                  \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    3 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Boønaa et al. (1992) \[[@B61]\]        EPA and DHA oil versus corn oil capsule                                                                                                                                    RCT parallel\               156 healthy subjects                                             5.1 g/day                                                    \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    10 weeks                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Richter et al. (1992) \[[@B55]\]       Omega-3 versus omega-6 capsule                                                                                                                                             RCT crossover\              26 healthy men                                                   5.0 g/day                                                    \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    3 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Tatò et al. (1993) \[[@B62]\]          EPA and DHA versus olive oil capsules                                                                                                                                      RCT crossover\              9 patients with familial hyperlipidemia                          3.0 and 4.5 g EPA and DHA/day                                \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    4 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Zampelas et al. (1994) \[[@B63]\]      SFA oil versus corn oil versus fish oil capsule                                                                                                                            RCT crossover\              12 healthy men                                                   40 g/day                                                     \(i\) No differences in postprandial serum apoA-I concentrations
                                                                                                                                                                                                                    1 day                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                              

  Eritsland et al. (1995) \[[@B64]\]     Fish oil capsule versus no capsule                                                                                                                                         RCT parallel\               511 patients with coronary artery disease                        4 g/day: 3.4 g EPA and DHA                                   \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    9 months                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Herrmann et al. (1995) \[[@B65]\]      Omega-3 versus rapeseed oil capsule                                                                                                                                        RCT parallel\               53 patients with coronary artery disease                         8.5 g/day                                                    \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    4 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Hamazaki et al. (1996) \[[@B66]\]      DHA versus control oil capsule                                                                                                                                             RCT parallel\               24 healthy subjects                                              1.5--1.8 g/day\                                              \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    13 weeks                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Grimsgaard et al. (1997) \[[@B78]\]    EPA versus DHA versus corn oil capsule                                                                                                                                     RCT parallel\               234 healthy men                                                  EPA: 3.8 g/day\                                              \(i\) 5.0% ↓ in fasting serum apoA-I concentrations comparing EPA with corn oil^*∗*^ \
                                                                                                                                                                                                                    7 weeks                                                                                      DHA: 3.6 g/day\                                              (ii) No differences in fasting serum apoA-I concentrations comparing DHA with corn oil^*∗*^
                                                                                                                                                                                                                                                                                                                 Corn oil: 4.0 g/day                                          

                                                                                                                                                                                                                                                                                                                                                                              

  Sorensen et al. (1998) \[[@B67]\]      Fish oil versus sunflower oil margarine                                                                                                                                    RCT parallel\               47 healthy subjects                                              4.0 g/day                                                    \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    4 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Buckley et al. (2004) \[[@B68]\]       EPA versus DHA versus olive oil capsules                                                                                                                                   RCT parallel\               42 healthy subjects                                              EPA: 4.8 g/day\                                              \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    4 weeks                                                                                      DHA: 4.9 g/day                                               

                                                                                                                                                                                                                                                                                                                                                                              

  Calabresi et al. (2004) \[[@B69]\]     Omega-3 versus placebo capsule                                                                                                                                             RCT crossover\              14 patients with familial hyperlipidemia                         EPA: 1.88 g/day\                                             \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    8 weeks                                                                                      DHA: 1.48 g/day                                              

                                                                                                                                                                                                                                                                                                                                                                              

  Shidfar et al. (2003) \[[@B72]\]       Omega-3 versus placebo                                                                                                                                                     RCT parallel\               68 hyperlipidemic patients                                       1 g/day                                                      \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    10 weeks                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Li et al. (2004) \[[@B79]\]            High versus low fish-fatty acids diet                                                                                                                                      RCT parallel\               22 healthy subjects                                              30 energy% of fat                                            \(i\) 14.0% ↑ in fasting plasma apoA-I concentrations comparing high with low fish-fatty acids consumption
                                                                                                                                                                                                                    24 weeks                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Goyens and Mensink (2006) \[[@B70]\]   ALA versus EPA and DHA capsule                                                                                                                                             RCT parallel\               37 elderly healthy subjects                                      ALA 6.8 g/day, EPA, and DHA: 1.05 + 0.55 g/day               \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    6 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  De Roos et al. (2008) \[[@B71]\]       Fish oil versus high oleic sunflower oil capsule                                                                                                                           RCT parallel\               81 healthy subjects                                              3.5 g/day: 700 mg EPA and 560 mg DHA                         \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    6 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Shidfar et al. (2008) \[[@B54]\]       Omega-3 versus 300 mg SFA, 100 mg MUFA, and 600 mg linoleic acid capsule                                                                                                   RCT parallel\               50 patients with diabetes mellitus type 2                        2 g/day: 520 mg EPA and 480 mg DHA                           \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    10 weeks                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Maki et al. (2011) \[[@B73]\]          Omega-3 versus soy oil                                                                                                                                                     RCT crossover\              31 patients with primary, isolated hypercholesterolemia          4 g/day                                                      \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    6 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Ooi et al. (2012) \[[@B74]\]           Therapeutic lifestyle change diet low versus high in fish (capsule)                                                                                                        RCT parallel\               20 healthy subjects                                              EPA and DHA: 1.23 g/day versus 0.27 g/day                    \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    24 weeks                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Song et al. (2013) \[[@B75]\]          High omega-3 and low omega-6 versus low omega-3 and high omega-6 fatty acid diet                                                                                           RCT crossover\              8 healthy and 8 hypertriacylglycerolemic subjects                0.97 versus 8.80 n-6/n-3 ratio                               \(i\) No differences in postprandial serum apoA-I concentrations
                                                                                                                                                                                                                    1 day                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                              

  Oliveira et al. (2014) \[[@B76]\]      Fish oil versus soya oil supplements                                                                                                                                       RCT parallel\               83 HIV-infected subjects on antiretroviral therapy               3 g/day: 540 mg EPA and 360 mg DHA                           \(i\) No differences in postprandial serum apoA-I concentrations
                                                                                                                                                                                                                    24 weeks                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Stewart et al. (1990) \[[@B88]\]       Mackerel versus lean meat                                                                                                                                                  RCT crossover\              84 healthy male subjects                                         135 g/day                                                    \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                                                                                                                    6 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Gascon et al. (1996) \[[@B84]\]        Lean fish (cod, sole, pollack, and haddock) versus animal protein (lean beef, pork, veal, eggs, skimmed milk, and milk products)                                           RCT crossover\              14 premenopausal healthy women                                   69--71 energy% protein                                       \(i\) No differences in lean fish on fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    4 weeks                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                              

  Lindqvist et al. (2007) \[[@B81]\]     Herring versus lean meat (pork and chicken)                                                                                                                                RCT crossover\              13 healthy obese subjects                                        50 g/day\                                                    \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    4 weeks                                                                                      5 days/week                                                  

                                                                                                                                                                                                                                                                                                                                                                              

  Erkkilä et al. (2008) \[[@B80]\]       Fatty (salmon, rainbow trout, Baltic herring, whitefish, vendace, and tuna) versus lean fish (pike, pike-perch, perch, saithe, and cod) versus lean meat (beef and pork)   RCT parallel\               33 patients with coronary heart disease                          100--150 g fish\                                             \(i\) 7.1 and 9.1% ↓ in fasting serum apoA-I concentrations comparing lean fish with lean meat or fatty fish consumption^*∗*^
                                                                                                                                                                                                                    8 weeks                                                                                      4 meals/week                                                 

                                                                                                                                                                                                                                                                                                                                                                              

  Isherwood et al. (2010) \[[@B83]\]     Prawns versus crab sticks                                                                                                                                                  RCT crossover\              23 healthy males                                                 225 g/day                                                    \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                                                                                    12 weeks                                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Percentages calculated from the mean values; EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, SFA: saturated fatty acids, and ALA: alpha lipoic acid.

###### 

Effect of fiber on fasting apoA-I concentrations.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                    Food component/product                                                                                              Study design and duration   Participants                                                        Intake                                                         Effect
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------- --------------------------- ------------------------------------------------------------------- -------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Anderson et al. (1991) \[[@B85]\]     Oat versus wheat bran diet (similar macronutrient composition)                                                      RCT parallel\               20 hypercholesterolemic men                                         14 g/day                                                       \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                            3 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Cara et al. (1992) \[[@B86]\]         Oat versus rice versus wheat bran versus wheat germ (similar macronutrient composition)                             RCT crossover\              6 healthy subjects                                                  10 g as oat, rice, and wheat bran versus 4.2 g as wheat germ   \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                            1 day                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                           

  Kashtan et al. (1992) \[[@B87]\]      Oat versus wheat bran supplemented food                                                                             RCT parallel\               32 subjects with a history of polypectomy and 32 healthy subjects   6.8 g/1000 kcal/day                                            \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                            2 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Stewart et al. (1992) \[[@B88]\]      Oat bran versus control diet (similar macronutrient composition)                                                    RCT crossover\              24 hypercholesterolemic subjects                                    50 g/day                                                       \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                            6 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Uusitupa et al. (1992) \[[@B89]\]     Oat versus wheat bran diet (similar macronutrient composition)                                                      RCT parallel\               36 hypercholesterolemic subjects                                    10.3 g/day                                                     \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                            8 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Zhang et al. (1992) \[[@B90]\]        Oat versus wheat bran                                                                                               RCT crossover\              9 subjects with ileostomies                                         4.9 versus 29.0 g/day                                          \(i\) No differences in plasma apoA-I concentrations
                                                                                                                                                            3 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Mekki et al. (1997) \[[@B91]\]        High-fiber diet versus low fiber diet                                                                               RCT parallel\               31 mildly hypercholesterolemic subjects                             35 g/day                                                       \(i\) No differences in plasma apoA-I concentrations
                                                                                                                                                            4 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Jenkins et al. (2002) \[[@B92]\]      Low fat, low-cholesterol diet high versus low in *β*-glucan or psyllium fiber (similar macronutrient composition)   RCT crossover\              68 hyperlipidemic subjects                                          8 g/day                                                        \(i\) 1.3% ↓ in serum apoA-I concentrations comparing the high with the low fibers^*∗*^
                                                                                                                                                            4 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Garcia et al. (2006) \[[@B93]\]       Arabinoxylan supplement versus placebo                                                                              RCT crossover\              11 patients with impaired glucose tolerance                         15 g/day                                                       \(i\) 4.0% ↓ in serum apoA-I concentrations^*∗*^
                                                                                                                                                            6 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Sola et al. (2007) \[[@B94]\]         Low SFA diet supplemented with P. ovata husk versus *P*. *ovata* seeds                                              RCT crossover\              28 men with CVD                                                     10.5 g/day                                                     \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                                                            8 week                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                           

  Rondanelli et al. (2008) \[[@B95]\]   *β*-Glucan versus rice bran supplemented food                                                                       RCT crossover\              24 mildly hypercholesterolemic men                                  15 versus 30 g/day                                             \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                            4 weeks                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                           

  Dodin et al. (2008) \[[@B96]\]        Flaxseed versus wheat germ                                                                                          RCT parallel\               199 healthy postmenopausal women                                    40 g/day                                                       \(i\) 4.0% ↓ in serum apoA-I concentrations comparing flaxseed with wheat germ^*∗*^
                                                                                                                                                            12 months                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Percentages calculated from the mean values; SFA: saturated fatty acids.

###### 

Effect of different nuts on fasting apoA-I concentrations.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                      Food component/product                                                                      Study design and duration                     Participants                                Intake                  Effects
  --------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------- ----------------------- -------------------------------------------------------------------------------------
  Munoz et al. (2001) \[[@B98]\]          Walnuts versus Mediteranean cholesterol-lowering diet (similar macronutrient composition)   RCT crossover\                                10 hypercholesterolemic men                 41--56 g/day            \(i\) No differences in serum apoA-I concentrations
                                                                                                                                      6 weeks                                                                                                           

                                                                                                                                                                                                                                                        

  Rajaram et al. (2009) \[[@B99]\]        Walnut versus control diet                                                                  RCT crossover\                                25 mildly hyperlipidemic subjects           42.5 g/day              \(i\) No differences in serum apoA-I concentrations
                                                                                                                                      4 weeks                                                                                                           

                                                                                                                                                                                                                                                        

  Aronis et al. (2012) \[[@B97]\]         Walnut versus control diet (similar macronutrient composition)                              RCT crossover\                                15 patients with metabolic syndrome         48 g/day                \(i\) 8.1% ↑ in serum apoA-I concentrations comparing walnut with control diet^*∗*^
                                                                                                                                      4 days                                                                                                            

                                                                                                                                                                                                                                                        

  Sabaté et al. (2003) \[[@B101]\]        Diet without versus low versus high in almonds                                              RCT crossover\                                25 healthy subjects                         0, 10, and 20 energy%   \(i\) No differences in serum apoA-I concentrations
                                                                                                                                      4 weeks                                                                                                           

                                                                                                                                                                                                                                                        

  Li et al. (2011) \[[@B100]\]            Almond versus NCEP^1^ diet                                                                  RCT crossover\                                20 patients with diabetes mellitus type 2   60 g/day                \(i\) No differences in plasma apoA-I concentrations
                                                                                                                                      12 weeks                                                                                                          

                                                                                                                                                                                                                                                        

  Mercanligil et al. (2007) \[[@B102]\]   Hazelnut versus low fat, low-cholesterol high-carbohydrate diet                             Period 1 control and period 2 intervention\   15 hypercholesterolemic men                 40 g/day                \(i\) No differences in plasma apoA-I concentrations
                                                                                                                                      4 weeks                                                                                                           

                                                                                                                                                                                                                                                        

  Tey et al. (2011) \[[@B103]\]           Ground versus sliced versus whole hazelnuts                                                 RCT crossover\                                48 mildly hypercholesterolemic subjects     30 g/day                \(i\) No differences in plasma apoA-I concentrations
                                                                                                                                      4 weeks                                                                                                           

                                                                                                                                                                                                                                                        

  Sheridan et al. (2007) \[[@B104]\]      Pistachio versus control diet (similar macronutrient composition)                           RCT crossover\                                15 mildly hypercholesterolemic subjects     56--85 g/day            \(i\) No differences in serum apoA-I concentrations
                                                                                                                                      4 weeks                                                                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Percentages calculated from the mean values; ^1^NCEP: National Cholesterol Education Program step II.

###### 

Effect of plant sterols on fasting apoA-I concentrations and apoA-I kinetics.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                            Food component/product                                                                                Study design and duration   Participants                                             Intake                           Effects
  --------------------------------------------- ----------------------------------------------------------------------------------------------------- --------------------------- -------------------------------------------------------- -------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Gylling and Miettinen (1994) \[[@B114]\]      Sitostanol versus control margarine                                                                   RCT crossover \             11 hypercholesterolemic diabetic men                     3.0 g/day                        \(i\) 4.3% in fasting serum apoA-I concentrations^*∗*^ \
                                                                                                                                                      6 weeks                                                                                                               (ii) No difference in apoA-I FCR

                                                                                                                                                                                                                                                                            

  Temme et al. (2001) \[[@B111]\]               Plant sterols enriched versus nonplant sterol enriched margarine                                      RCT crossover \             42 mildly hypercholesterolemic subjects                  2.0 g/day                        \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                      4 weeks                                                                                                               

                                                                                                                                                                                                                                                                            

  Amundsen et al. (2002) \[[@B105]\]            Plant sterol esters versus control with similar fatty acid composition                                RCT crossover  \            38 children with familial hypercholesterolemia           1.6 g/day                        \(i\) No differences in plasma apoA-I concentrations
                                                                                                                                                      8 weeks                                                                                                               

                                                                                                                                                                                                                                                                            

  Chan et al. (2007) \[[@B113]\]                Olive oil versus sunflower oil with plant sterols versus olive oil with plant sterols margarine       RCT crossover  \            21 moderately overweight, hypercholesterolemic subject   70% of total fat in the diet \   \(i\) 0.8% ↑ in fasting plasma apoA-I concentrations comparing olive oil with plant sterols with olive oil alone or sunflower oil with plant sterols^*∗*^
                                                                                                                                                      4 weeks                                                                              1.7 g plant sterols/day          

                                                                                                                                                                                                                                                                            

  Madsen et al. (2007) \[[@B107]\]              Plant sterols versus control with similar fatty acid composition                                      RCT crossover \             46 mildly hypercholesterolemic subjects                  2.3 g/day                        \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                      4 weeks                                                                                                               

                                                                                                                                                                                                                                                                            

  Ooi et al. (2007) \[[@B108]\]                 Plant sterols enriched versus nonplant sterol enriched margarine and cereals                          RCT crossover \             9 patients with the metabolic syndrome                   2.0 g/day                        \(i\) No differences in plasma apoA-I concentrations \
                                                                                                                                                      4 weeks                                                                                                               (ii) No effect on apoA-I PR  \
                                                                                                                                                                                                                                                                            (iii) No effect on apoA-I FCR

                                                                                                                                                                                                                                                                            

  Hernández-Mijares et al. (2010) \[[@B106]\]   Healthy diet (NCEP)^1^ versus healthy diet with plant sterols versus normal diet with plant sterols   RCT parallel  \             84 mildly hypercholesterolemic subjects                  2.0 g/day                        \(i\) 4.0% ↑ in serum apoA-I concentration comparing prudent diet with plant sterols with prudent diet alone or normal diet with plant sterols^*∗*^
                                                                                                                                                      3 months                                                                                                              

                                                                                                                                                                                                                                                                            

  Söderholm et al. (2010) \[[@B110]\]           Rye bread with low versus high versus no plant sterols                                                RCT parallel \              68 healthy subjects                                      2.0 versus 4.0 g/day             \(i\) No differences in serum apoA-I concentrations
                                                                                                                                                      2 weeks                                                                                                               

                                                                                                                                                                                                                                                                            

  Gagliardi et al. (2010) \[[@B112]\]           Plant sterol margarines versus no-trans-FA margarine versus butter                                    RCT parallel \              53 subjects with metabolic syndrome                      2.4 g/day                        \(i\) No differences in plasma apoA-I concentrations
                                                                                                                                                      5 weeks                                                                                                               

                                                                                                                                                                                                                                                                            

  Sialvera et al. (2012) \[[@B109]\]            Yogurt beverage with versus without phytosterol                                                       RCT parallel \              108 patients with the metabolic syndrome                 4.0 g/day                        \(i\) No differences in plasma apoA-I concentrations
                                                                                                                                                      2 months                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Percentages calculated from the mean values; ^1^NCEP: National Cholesterol Education Program.

###### 

Effect of soy protein or isoflavone in soy on apoA-I concentrations.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                         Food component/product                                                         Study design and duration   Participants                                                Intake                                                Effect
  ------------------------------------------ ------------------------------------------------------------------------------ --------------------------- ----------------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Bakhit et al. (1994) \[[@B115]\]           Soybean protein with or without soybean fiber                                  RCT crossover\              21 hypercholesterolemic men                                 25 g/day                                              \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                            4 weeks                                                                                                                                       

                                                                                                                                                                                                                                                                          

  Kurowska et al. (1997) \[[@B120]\]         Soy protein versus milk protein                                                RCT crossover\              34 hypercholesterolemic subjects                            2% of daily intake                                    \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                            4 weeks                                                                                                                                       

                                                                                                                                                                                                                                                                          

  Nilausen and Meinertz (1998) \[[@B124]\]   Soy protein versus casein (similar macronutrient composition)                  RCT crossover\              9 healthy men                                               154 g/day                                             \(i\) 10.7% ↑ in fasting plasma apoA-I concentrations^*∗*^
                                                                                                                            1 month                                                                                                                                       

                                                                                                                                                                                                                                                                          

  Jenkins et al. (2000) \[[@B119]\]          Soy incorporated into breakfast cereals versus no soy                          RCT crossover\              25 hyperlipidemic subjects                                  36 g/day                                              \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                            3 weeks                                                                                                                                       

                                                                                                                                                                                                                                                                          

  Chen et al. (2006) \[[@B116]\]             Soy protein versus milk protein                                                RCT parallel\               26 patients undergoing hypercholesterolaemic hemodialysis   30 g/day                                              \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                            3 months                                                                                                                                      

                                                                                                                                                                                                                                                                          

  McVeigh et al. (2006) \[[@B121]\]          Soy protein varying in isoflavone content                                      RCT crossover\              35 healthy young men                                        1.64--61.7 mg isoflavone/day                          \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                            57 days                                                                                                                                       

                                                                                                                                                                                                                                                                          

  Pipe et al. (2009) \[[@B122]\]             Soy protein isolate versus milk protein isolate                                RCT crossover\              29 patients with diabetes mellitus type 2                   80 g/day                                              \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                            57 days                                                                                                                                       

                                                                                                                                                                                                                                                                          

  Campbell et al. (2010) \[[@B125]\]         Soy protein products versus casein products                                    RCT parallel\               62 moderately hypercholesterolemic postmenopausal women     25 g/day                                              \(i\) 8.5% ↓ in fasting serum apoA-I concentrations^*∗*^
                                                                                                                            1 year                                                                                                                                        

                                                                                                                                                                                                                                                                          

  Tabibi et al. (2010) \[[@B123]\]           Soy protein versus no soy protein                                              RCT parallel\               40 peritoneal dialysis patients                             28 g/day                                              \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                            8 weeks                                                                                                                                       

                                                                                                                                                                                                                                                                          

  Jenkins et al. (2002) \[[@B118]\]          High versus low isoflavone soy protein                                         RCT crossover\              41 hyperlipidemic subjects                                  Soy: 50--52 g/day; isoflavones: 73 versus 10 mg/day   \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                                            1 months                                                                                                                                      

                                                                                                                                                                                                                                                                          

  Cicero et al. (2002) \[[@B117]\]           Soy proteins supplemented with isolated *β*-sitosterol versus no soy protein   RCT parallel\               20 moderately hypercholesterolemic subjects                 10 g/day                                              \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                            40 days                                                                                                                                       

                                                                                                                                                                                                                                                                          

  Matthan et al. (2007) \[[@B127]\]          Different sources of soy protein versus animal protein                         RCT crossover\              28 hypercholesterolemic subjects                            6.8--7.5 energy%/day                                  \(i\) 2.0% ↑ in fasting plasma apoA-I concentrations comparing soy-milk with soybean and soy flour\
                                                                                                                            6 weeks                                                                                                                                       (ii) No differences in fasting plasma apoA-I concentrations comparing soy with animal protein

                                                                                                                                                                                                                                                                          

  Bakhtiary et al. (2012) \[[@B126]\]        Soy protein versus soy nuts versus no soy                                      RCT parallel\               75 women with the metabolic syndrome                        35 g/day                                              \(i\) 18.8% ↑ in fasting serum apoA-I concentrations comparing soy protein with control^*∗*^ \
                                                                                                                            3 months                                                                                                                                      (ii) 25.0% ↑ in fasting serum apoA-I concentrations comparing soy nuts with control^*∗*^

                                                                                                                                                                                                                                                                          

  Wangen et al. (2001) \[[@B129]\]           No versus low versus high soy isoflavone                                       RCT crossover\              18 mildly hypercholesterolemic women                        7.1, 65, 132 mg/day                                   \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                                            3 months                                                                                                                                      

                                                                                                                                                                                                                                                                          

  Santo et al. (2010) \[[@B128]\]            Milk protein versus isoflavone-poor soy versus isoflavone-rich soy             RCT crossover\              30 healthy young men                                        25 g protein/day                                      \(i\) No differences in fasting and postprandial plasma apoA-I concentrations
                                                                                                                            28 days                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Percentages calculated from the mean values.

###### 

Effect of other food components or products on apoA-I concentrations.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                     Food component/product                                                Study design and duration   Participants                                Intake                                                                                                Effects
  -------------------------------------- --------------------------------------------------------------------- --------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sacks et al. (1984) \[[@B130]\]        Eggs versus no foods containing eggs                                  RCT crossover\              17 healthy subjects                         400 kcal/day                                                                                          \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                               3 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Luley et al. (1986) \[[@B131]\]        Dried garlic versus control                                           RCT crossover\              \(i\) 34 hyperlipidemic patients            3 × 198 mg/day                                                                                        \(i\) Both no differences in fasting serum apoA-I concentrations
                                                                                                               6 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Luley et al. (1986) \[[@B131]\]        Dried garlic versus control                                           RCT crossover\              \(i\) 51 hyperlipidemic patients            3 × 450 mg/day                                                                                        \(i\) Both no differences in fasting serum apoA-I concentrations
                                                                                                               6 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Hughes et al. (1994) \[[@B133]\]       Beta-carotene versus wheat germ oil capsules                          RCT parallel\               59 hyperlipidemic patients\                 300 mg/day                                                                                            \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                               30 days                     36 healthy subjects                                                                                                                               

                                                                                                                                                                                                                                                                                             

  Nanjee et al. (1996) \[[@B134]\]       Glucosinolate free vegetable versus Brussels sprouts                  RCT parallel\               10 healthy men                              300 g/day                                                                                             \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                               3 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Nanjee et al. (1996) \[[@B134]\]       Eugenol versus placebo capsule                                        RCT parallel\               10 healthy men                              150 mg/day                                                                                            \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                               3 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Neil et al. (1996) \[[@B132]\]         Dried garlic versus placebo powder                                    RCT parallel\               115 hypercholesterolemic subjects           900 mg/day                                                                                            \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                               6 months                                                                                                                                                                      

                                                                                                                                                                                                                                                                                             

  Itoh et al. (1997) \[[@B135]\]         Magnesium versus placebo supplement                                   RCT parallel\               33 healthy subjects                         411--548 mg/day                                                                                       \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                               4 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Guimarães et al. (2000) \[[@B136]\]    Eggplant versus placebo powder                                        RCT parallel\               38 hypercholesterolemic subjects            12 g powder/day, corresponded with 100 g eggplant/day                                                 \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                               5 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Oosthuizen et al. (2000) \[[@B137]\]   Dry beans versus no beans                                             RCT crossover\              22 hyperlipidemic patients                  110 g/day                                                                                             \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                               4 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Gammon et al. (2012) \[[@B138]\]       Healthy diet with versus without green kiwifruits                     RCT crossover\              85 hypercholesterolemic men                 2 kiwifruits/day                                                                                      \(i\) No differences in fasting serum apoA-I concentrations
                                                                                                               4 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Mullan et al. (2016) \[[@B139]\]       Polyphenols versus control                                            RCT parallel\               20 healthy overweight or obese subjects     250 ml (361 mg) polyphenols + 120 mg vitamin C                                                        \(i\) No differences in fasting plasma apoA-I concentrations
                                                                                                               4 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Ohlsson et al. (2010) \[[@B140]\]      Sphingolipids versus placebo                                          RCT parallel\               18 healthy men                              40 g high fat meal\                                                                                   \(i\) No differences in postprandial plasma apoA-I concentrations
                                                                                                               1 day                                                                   975 mg milk sphingolipids                                                                             

                                                                                                                                                                                                                                                                                             

  Castilla et al. (2006) \[[@B141]\]     Red grape juice versus no juice                                       RCT parallel\               26 hemodialysis patients\                   100 ml/day                                                                                            \(i\) 13.2% ↑ in fasting plasma apoA-I concentrations comparing juice with no juice consumption in hemodialysis patients^*∗*^ \
                                                                                                               2 weeks                     12 hemodialysis control patients\                                                                                                                 (ii) 63.2% ↑ in fasting plasma apoA-I concentrations comparing juice consumption in healthy subjects with no juice consumption in hemodialysis patients^*∗*^
                                                                                                                                           15 healthy subjects                                                                                                                               

                                                                                                                                                                                                                                                                                             

  Roza et al. (2007) \[[@B142]\]         Citrus flavonoids with tocotrienols versus placebo                    RCT parallel\               120 hypercholesterolemic subjects           270 mg citrus flavonoids + 30 mg tocotrienols/day                                                     \(i\) 5.0% ↑ in fasting plasma apoA-I concentrations
                                                                                                               12 weeks                                                                                                                                                                      

                                                                                                                                                                                                                                                                                             

  Salehpour et al. (2012) \[[@B143]\]    Vitamin D3 versus control supplement                                  RCT parallel\               77 healthy overweight or obese subjects     25 mg/day                                                                                             \(i\) 9.2% ↑ in fasting serum apoA-I concentrations^*∗*^
                                                                                                               12 weeks                                                                                                                                                                      

                                                                                                                                                                                                                                                                                             

  Heravifard et al. (2013) \[[@B144]\]   Vitamin D versus calcium and vitamin D versus control                 RCT parallel\               90 patients with diabetes mellitus type 2   150 mg calcium versus150 mg calcium and 500 IU vitamin D versus 250 mg calcium and 500 IU vitamin D   \(i\) 18% ↑ in fasting serum apoA-I concentrations comparing vitamin D with control^*∗*^ \
                                                                                                               12 weeks                                                                                                                                                                      (ii) 16% ↑ in fasting serum apoA-I concentrations comparing vitamin D with calcium with control^*∗*^

                                                                                                                                                                                                                                                                                             

  Neufingerl et al. (2013) \[[@B145]\]   Theobromine versus placebo                                            RCT parallel\               152 healthy subjects                        0, 150, 850, and 1000 mg/day                                                                          \(i\) 7.6% ↑ in fasting serum apoA-I concentrations comparing 850 mg theobromine with placebo^*∗*^
                                                                                                               4 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Constans et al. (2015) \[[@B146]\]     Orange juice versus control                                           RCT crossover\              25 male subjects with 2 CVD risk factors    3 × daily 200 ml                                                                                      \(i\) 6.2% ↑ in fasting plasma apoA-I concentrations comparing orange juice with placebo^*∗*^
                                                                                                               4 weeks                                                                                                                                                                       

                                                                                                                                                                                                                                                                                             

  Han et al. (2016) \[[@B147]\]          Low versus high dose of grape pomace and omija fruit versus control   RCT parallel\               76 healthy overweight or obese subjects     342.5 versus 685.0 mg grape pomace/day and 57.5 versus 115.0 mg omija/day                             \(i\) 10% ↑ in fasting plasma apoA-I concentrations after the high dose compared with control^*∗*^ \
                                                                                                               10 weeks                                                                                                                                                                      (ii) No difference in fasting plasma apoA-I concentrations after the low dose compared with control
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Percentages calculated from the mean values.

###### 

Summary of the pharmacological approaches targeting apoA-I metabolism in humans.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                                                    Infusion                                                          Duration                               Model                                                                               Dose                                                             Effect
  --------------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------- ----------------------------------------------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------
  Bloedon et al. (2008) \[[@B156]\]                                     D-4F                                                              A single dose                          Coronary artery diseased patients                                                   30 versus 100 versus 300 versus 500 mg                           \(i\) ↑ anti-inflammatory activity of HDL

                                                                                                                                                                                                                                                                                                                                      

  Nissen et al. (2003) \[[@B157]\]                                      ApoA-I Milano                                                     One infusion for 5 weeks               Patients with acute coronary syndromes                                              15 versus 45 mg/kg                                               \(i\) 15.1 mm^3^ and 12.6 mm^3^↓ in atheroma volume

                                                                                                                                                                                                                                                                                                                                      

  Kempen et al. (2016) and Kallend et al. (2016) \[[@B159], [@B160]\]   ApoA-I Milano                                                     5 doses during 2 hours                 Patients with stable coronary artery disease                                        10 versus 20 versus 30 versus 40 mg/kg                           \(i\) Dose-dependent ↑ in apoA-I concentrations\
                                                                                                                                                                                                                                                                                                                                      (ii) Dose-dependent shift from small- to large-sized HDL particles.\
                                                                                                                                                                                                                                                                                                                                      (iii) ↑ in ABCA1-mediated cholesterol efflux

                                                                                                                                                                                                                                                                                                                                      

  Nicholls (2016) \[[@B161]\]                                           ApoA-I Milano                                                     5 weekly doses                         120 patients with a recent acute coronary syndrome                                  20 mg/kg                                                         \(i\) 7.8 and 5.3% ↓ in fasting HDL-C and apoA-I concentrations\
                                                                                                                                                                                                                                                                                                                                      (ii) No effects on percent and total atheroma volume

                                                                                                                                                                                                                                                                                                                                      

  Nicholls (2007) \[[@B161]\]                                           CSL-111                                                           Once a week for a month                Patients elected for coronary angiography                                           40 versus 80 mg/kg                                               \(i\) Abnormalities in liver function test\
                                                                                                                                                                                                                                                                                                                                      (ii) 3.4% ↓ in atheroma volume

                                                                                                                                                                                                                                                                                                                                      

  Easton et al. (2014) and Gille et al. (2014) \[[@B163], [@B164]\]     CSL112                                                            A single dose                          Healthy volunteers                                                                  5 versus 15 versus 40 versus 70 versus 105 versus 135 mg/kg      \(i\) ↑ in apoA-I concentrations for 3 days or longer\
                                                                                                                                                                                                                                                                                                                                      (ii) 81% ↑ in HDL concentrations\
                                                                                                                                                                                                                                                                                                                                      (iii) ↑ pre-*β*-HDL particle concentrations\
                                                                                                                                                                                                                                                                                                                                      (iv) 2.9-fold ↑ in cholesterol efflux

                                                                                                                                                                                                                                                                                                                                      

  Easton et al. (2014) and Gille et al. (2014) \[[@B163], [@B164]\]     CSL112                                                            Once or twice weekly for 4 weeks       Healthy volunteers                                                                  3.4 versus 6.7 g once a week versus 3.4 g twice a week           \(i\) ↑ in apoA-I concentrations for 3 days or longer\
                                                                                                                                                                                                                                                                                                                                      (ii) ↑ pre-*β*-HDL particle concentrations\
                                                                                                                                                                                                                                                                                                                                      (iii) 2.6-fold ↑ in cholesterol efflux

                                                                                                                                                                                                                                                                                                                                      

  Tricoci et al. (2015) \[[@B166]\]                                     CSL112                                                            A single dose                          Patients with atherosclerosis                                                       1.7 versus 3.4 versus 6.8 g                                      \(i\) No elevations in alanine aminotransferase or aspartate aminotransferase\
                                                                                                                                                                                                                                                                                                                                      (ii) No serious adverse events.\
                                                                                                                                                                                                                                                                                                                                      (iii) Dose-dependent ↑ in apoA-I concentrations and total cholesterol efflux

                                                                                                                                                                                                                                                                                                                                      

  Gibson et al. (2016) \[[@B165]\]                                      CSL112                                                            4 weekly infusions                     Patients with myocardial infarction                                                 0 versus 2 versus 6 g                                            \(i\) Safe for use\
                                                                                                                                                                                                                                                                                                                                      (ii) Dose-dependent ↑ in fasting apoA-I, HDL-C concentrations and cholesterol efflux

                                                                                                                                                                                                                                                                                                                                      

  Tardif (2014) \[[@B167]\]                                             CER-001                                                           6 weekly infusions                     Patients with acute coronary syndromes                                              3 versus 6 versus 12 mg/kg                                       \(i\) No changes in atheroma volumes

                                                                                                                                                                                                                                                                                                                                      

  Kootte et al. (2015) \[[@B168]\]                                      CER-001                                                           9 infusions twice weekly for 28 days   Patients with familial hypoalphalipoproteinemia                                     8 mg/kg                                                          \(i\) 94% ↑ in apoA-I concentrations\
                                                                                                                                                                                                                                                                                                                                      (ii) 117% ↑ in HDL-C concentrations\
                                                                                                                                                                                                                                                                                                                                      (iii) 8.8% ↓ atherosclerotic lesion size\
                                                                                                                                                                                                                                                                                                                                      (iv) 44% ↑ in cholesterol efflux\
                                                                                                                                                                                                                                                                                                                                      (v) ↑ fecal neutral sterol excretion

                                                                                                                                                                                                                                                                                                                                      

  Hovingh et al. (2015) \[[@B169]\]                                     CER-001                                                           12 infusions twice weekly              Patients with homozygous familial hypercholesterolemia                              8 mg/kg                                                          \(i\) 13% ↑ in apoA-I concentrations^*∗*^ \
                                                                                                                                                                                                                                                                                                                                      (ii) 2.8% ↓ in vessel wall area^*∗*^ \
                                                                                                                                                                                                                                                                                                                                      (iii) Trend toward ↓ in vessel wall thickness

                                                                                                                                                                                                                                                                                                                                      

  Zheng et al. (2016) \[[@B170]\]                                       CER-001                                                           A single dose                          Patients with atherosclerotic carotid artery disease                                3 mg/kg                                                          \(i\) 8.7% ↑ in apoA-I concentrations^*∗*^ \
                                                                                                                                                                                                                                                                                                                                      (ii) 13.8% ↑ in the cholesterol efflux capacity

                                                                                                                                                                                                                                                                                                                                      

  Nicholls et al. 2017 \[[@B171]\]                                      CER-001                                                           10 weekly infusions                    Coronary artery diseased patients                                                                                                                    \(i\) No difference in atheroma volume\
                                                                                                                                                                                                                                                                                                                                      (ii) No difference in LDL-C

                                                                                                                                                                                                                                                                                                                                      

  Bloedon et al. (2008) \[[@B156]\]                                     D-4F                                                              A single dose                          Coronary artery diseased patients                                                   30 versus 100 versus 300 versus 500 mg                           \(i\) ↑ anti-inflammatory activity of HDL

                                                                                                                                                                                                                                                                                                                                      

  Bailey et al. (2010) \[[@B172]\]                                      RVX-208                                                           7 days                                 Healthy subjects                                                                    1 to 20 mg/kg/day                                                \(i\) 11% ↑ in apoA-I concentrations\
                                                                                                                                                                                                                                                                                                                                      (ii) 11% ↑ in HDL-C concentrations\
                                                                                                                                                                                                                                                                                                                                      (iii) 42% ↑ in pre-*β*1-HDL concentrations\
                                                                                                                                                                                                                                                                                                                                      (iv) 11% ↑ in ABCA1-mediated cholesterol efflux

                                                                                                                                                                                                                                                                                                                                      

  Nicholls et al. (2011) \[[@B173]\]                                    RVX-208                                                           Twice daily for 12 weeks               Patients with stable coronary artery disease                                        50 versus 100 versus 150 mg                                      \(i\) No difference in apoA-I concentrations

                                                                                                                                                                                                                                                                                                                                      

  Gilham et al. (2016) \[[@B174]\]                                      RVX-208                                                           24 weeks                               Statin-treated patients with low HDL-C concentrations                               200 mg/day                                                       \(i\) ↑ in apoA-I concentrations\
                                                                                                                                                                                                                                                                                                                                      (ii) ↑ HDL particle number\
                                                                                                                                                                                                                                                                                                                                      (iii) Safe for oral use

                                                                                                                                                                                                                                                                                                                                      

  Nicholls et al. (2016) \[[@B32]\]                                     RVX-208                                                           26 weeks                               Statin-treated patients with coronary artery disease and low HDL-C concentrations   100 mg twice daily                                               \(i\) No difference in atheroma volume, HDL-C, and apoA-I concentrations

                                                                                                                                                                                                                                                                                                                                      

  Siebel et al. (2016) \[[@B175]\]                                      RVX-208                                                           29--33 days                            20 males with prediabetes                                                           100 mg                                                           \(i\) No change in HDL-C and apoA-I concentrations\
                                                                                                                                                                                                                                                                                                                                      (ii) 11% ↑ in medium size HDL particles\
                                                                                                                                                                                                                                                                                                                                      (iii) 10% ↓ in small size HDL particles\
                                                                                                                                                                                                                                                                                                                                      (iv) Later and ↑ glucose peak\
                                                                                                                                                                                                                                                                                                                                      (v) ↓ endogenous glucose production

                                                                                                                                                                                                                                                                                                                                      

  Shamburek et al. (2016) \[[@B176]\]                                   Recombinant human lecithin-cholesterol acyltransferase infusion   7 months                               1 patient with familial lecithin-cholesterol acyltransferase deficiency             Optimization phase: 3 times, 1 hour, 0.3, 3.0, and 9.0 mg/kg.\   \(i\) ↑ apoA-I, HDL-C, and to a lesser extent LDL-C\
                                                                                                                                                                                                                                                                     Maintenance phase: every 1 to 2 weeks, 3.0 or 9.0 mg/kg          (ii) ↑ postprandial triacylglycerol concentrations
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Percentages calculated from the mean values.

[^1]: Academic Editor: Michael B. Zemel
